NAP Known Limitations and Development Roadmap
Nutraceutical Assisted Programs
A Companion to the NAP Manifesto What the Category Has Not Yet Done, and When It Will An Instrument of Transparency for Partners, Regulators, and Funders Michael Andrew Feller Jones Founder, Nutraceutical Assisted Programs Category
About This Document
Every founding framework has gaps. Most hide them. NAP names them.
This document is the honest ledger of what the NAP category has not yet built, has not yet proven, or has not yet resolved — and the sequenced plan for addressing each. It exists because the fastest way to lose a sophisticated partner, regulator, or funder is to present a new medical category as finished, and the surest way to earn their trust is to demonstrate that the category knows precisely where its own limits are.
This is the same discipline that gives the NAP Evidence Compendium its credibility. The Compendium does not claim the integrated cascade is proven; it states plainly that it is a hypothesis under test. This document applies that exact honesty to the whole model. A reader should finish it more confident in NAP, not less — because a framework that can name its own gaps this precisely is a framework that can be trusted to close them.
PART I. THE PRINCIPLE OF STATED LIMITATIONS
A category that pretends to completeness invites the discovery of its flaws by others, on their terms. A category that names its own limitations controls the conversation, demonstrates self-awareness, and converts every gap from a vulnerability into a roadmap item. NAP chooses the second path deliberately.
Each limitation below is presented in the same structure: the limitation stated without minimization, NAP's current position on it, and its status — whether it is addressed now, positioned (a stance is set and the full build scales with the category), or on the roadmap (deliberately sequenced to a later development phase, because addressing it before the category has the scale to support it would be premature).
The sequencing is not avoidance. It is the recognition that a founding-stage category must first prove it works and practice safely before it expands to every population and every market. Proof and safety come first. Scale follows proof.
PART II. THE LIMITATIONS LEDGER
Addressed Now
1. The integrated cascade is not yet proven by NAP's own outcome data. Current position: Each link in the cascade is documented in peer-reviewed research; the integrated cascade as a unified clinical hypothesis, and the comparative effectiveness of comprehensive NAP protocols, are not. NAP states this openly. Status: Addressed now. The NAP Outcome Registry and Evidence-Generation Framework establishes the proof engine, beginning at the founding pilot center. This is the category's first operational priority.
2. NAP uses some diagnostic tests that conventional science contests. Current position: Certain tests used in integrative practice — notably hair tissue mineral analysis and provoked urine metal testing — lack validated reference standards and are contested. Status: Addressed now. The Evidence Compendium's Diagnostic Validity standard classifies every test by validity tier, requires that assessment lead with validated assays, and bars contested tests from ever standing alone. NAP gets ahead of the criticism by making it first.
3. The legal authority to practice NAP was not explicitly bounded. Current position: Ordering and interpreting laboratory testing and de-prescribing are licensed medical acts. NAP must not appear to authorize the unlicensed practice of medicine. Status: Addressed now. The NAP Clinical Safety and Practice Standards make a primary clinical license a hard requirement, establish that scope follows that license, and confine de-prescribing to the supervising prescriber.
4. The boundary with acute and emergency care was not stated as a universal rule. Current position: Terrain-first care is for chronic, multifactorial conditions and must never delay care for acute or dangerous presentations. Status: Addressed now. The Clinical Safety and Practice Standards establish a universal red-flag rule and an explicit acute-care boundary, binding on every practitioner.
Positioned (stance set; full system scales with the category)
5. System-wide safety surveillance is not yet operating at scale. Current position: A new medical category must be able to detect and act on harm across its whole network, not only at the practitioner level. Status: Positioned. The Clinical Safety and Practice Standards establish the duty to report, the adverse-event registry design, herb–drug interaction surveillance, and the safety signal loop now. The full pharmacovigilance capability scales as the accredited network grows — there is no global system to operate until there is a network to monitor.
6. Product quality cannot yet be enforced across a supply chain NAP does not control. Current position: Natural products are a documented source of the very contaminants NAP works to remove; a quality floor is therefore clinical, not optional. Status: Positioned. The product-quality and sourcing standard — identity, contaminant, potency, GMP, and third-party verification — is published now and is product-neutral. Enforcement deepens as accreditation and supplier relationships mature.
On the Roadmap (sequenced to a later development phase)
7. NAP risks being expensive, cash-pay medicine accessible mainly to the affluent. Current position: Comprehensive testing and natural protocols are costly. A model "for the next generation" that only the wealthy can reach fails its own mission. Status: Roadmap — Expansion phase. NAP will define an essential-NAP minimum-viable protocol, sliding-scale and access models, and adaptations for low-resource and global-south settings. This is deferred deliberately: an access model is built once a validated, affordable core protocol exists to make accessible.
8. The model is adult, individual, and treatment-focused; it lacks a prevention and next-generation arm. Current position: The cascade is driven by environmental, food, and water exposures that treating one adult at a time cannot fix, and "the next generation" implies children, who are not yet served. Status: Roadmap — Integration phase. NAP will develop a developmental-origins (prenatal, maternal, pediatric) arm and a population and environmental-policy layer that addresses toxic burden at its source. This is the largest expansion of the model and is correctly sequenced after the adult clinical model is proven and safe.
9. The model is built largely on the United States regulatory landscape. Current position: NAP is global in ambition, but its strategy leans on US institutions, and India's AYUSH and China's TCM are already state-recognized systems with which NAP must federate, not compete. Status: Roadmap — Expansion and Integration phases. NAP will develop regional regulatory playbooks and concrete federation agreements with existing national systems. The federation principle is set; the operational, jurisdiction-by-jurisdiction execution scales with the coalition.
PART III. SEQUENCING AGAINST THE BUILD ROADMAP
These items map to the phased build roadmap defined in the Strategic Infrastructure Architecture:
- Foundation Phase (Years 1–2): Items 1–6. Launch the outcome registry; publish the diagnostic, scope, acute-care, safety, and product-quality standards; operate them at the founding pilot. Prove it works and practice it safely.
- Expansion Phase (Years 3–5): Items 7 and 9 (begin). Multi-site outcome replication; the essential-NAP access model; the first regional regulatory playbooks and federation agreements.
- Integration Phase (Years 6–8): Items 8 and 9 (deepen). The developmental-origins and pediatric arm; the population and environmental-policy layer; mature federation with national systems.
- Maturation Phase (Years 9–10): Comparative outcome evidence in hand; the limitations of the founding period substantially closed; NAP operating as a recognized, evidence-based, globally federated standard.
CLOSING
A category of medicine is not trusted because it claims to be complete. It is trusted because it knows, precisely and without flinching, what it is not yet — and because it has a credible, sequenced plan to close the distance. This document is that knowledge and that plan, stated openly.
The gaps named here are real. They are also, every one of them, addressed now, positioned, or scheduled. That is the difference between a framework with weaknesses and a framework with a roadmap. NAP is the second.